Drugs / DCB07010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03293732 | Nov 2012 → Mar 2013 | influenza | Advagene Biopharma Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCB07010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03293732 ↗ |
| Modality | Protein / enzyme biologic | “A protein based adjuvant originated from prokaryotic organism.” NCT03293732 ↗ |
| Route | Intranasal | “when given intranasally at escalating dose levels of 7.5μg, 15μg, 30μg and 45μg” NCT03293732 ↗ |